Cardiovascular Diseases

818 trials 341 recruiting

Filter these 818 trials by phase, country and sponsor.

Open in Search →

A clinical study of MK-7228 in healthy men (MK-7228-001) Ended

2024-520214-22-00 Atherosclerosis 1 2025-03-24
TGD001 SAD study in healthy volunteers Ended

2024-514931-63-00 A Phase I randomized, double-blind, placebo-controlled 1 2025-03-14
A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1) Ended

2024-515864-30-00 Heterozygous familial hypercholesterolemia 4 2025-03-12
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4… Ended

2024-516840-24-00 Chronic Kidney disease 3 2025-03-05
Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults. Ended

2024-515285-14-00 Healthy Volunteers 1 2025-03-04
A Study to Understand the ability and safety of GDC-8264 in Preventing kidney Injury and Major Adverse Kidney Events following Heart Surgery Ended

2024-513125-23-00 Patients with moderate to high risk for cardiac surgery 4 2025-02-28
Measuring the macro- and microvascular responses to LPS and exenatide Ended

2024-519014-31-00 Cardiovascular and metabolic diseases 3 2025-02-26
Impact of trimetazidine on endothelial function and biomarkers correlating with the prognosis of heart failure with preserved ejection fract… Ended

2023-506138-65-00 Heart failure with preserved ejection fraction 6 2025-02-20
Efficacy of tocilizumab in the treatment of acute anterior ischemic optic neuropathy optic neuropathy in Horton's disease Ended

2024-519977-20-00 Acute Anterior Ischemic Optic Neuropathy associated wit 4 2025-01-27
A clinical study of MK-2828 in healthy people (MK-2828-002) Ended

2024-518229-13-00 Atherosclerosis 3 2025-01-21
A Multicenter, Randomized, Placebo-Controlled, Parallel Group Trial on the Safety and Efficacy of Istaroxime for Cardiogenic Shock SCAI Stag… Ended

2023-507243-11-02 Cardiogenic Shock 4 2025-01-05
Mass balance study of [14C]-VAD044 Ended

2024-518843-39-00 Vascular malformation 3 2024-12-31
GENPAD Ended

2024-518122-33-00 Peripheral Arterial Disease 6 2024-12-13
The SORT OUT XII DAPT Duration Trial Ended

2024-515236-69-00 Acute coronary syndromes 11 2024-12-13
A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-024) Ended

2024-512278-92-00 Pulmonary Arterial Hypertension (PAH) 4 2024-12-09
ARETHA: cARdiomems vEriciguaT Heart fAilure (A double-blind randomized placebo-controlled trial of vericiguat in heart failure patients with… Ended

2024-514111-10-00 Heart failure with reduced ejection fraction (HFrEF) 6 2024-12-06
Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome Ended

2024-515060-32-00 Takotsubo syndrome 5 2024-11-22
Mangafodipir - an intracellular contrast agent for Magnetic Resonance Imaging (MRI): Measuring manganese uptake rate in heart failure patien… Ended

2023-508118-40-01 Heart Failure 4 2024-11-22
Lowering of LDL-C with rosuvastatin or single-pill combination rosuvastatin/ezetimibe in high/very high-risk patients with hyperlipidaemia –… Ended

2023-504914-31-00 Hyperlipidaemia 11 2024-11-10
DECISION; Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands Ended

2023-509898-23-00 heart failure 6 2024-11-01
A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazana… Ended

2024-510856-11-00 Chronic kidney disease 3 2024-10-31
Effect of Camostat for Kidney Protection in Chronic Kidney Disease (CamKid). Ended

2023-508516-34-00 Chronic Kidney Disease with proteinuria 4 2024-10-30
An Early Phase Study to Investigate the Safety and Efficacy of HS135 in Adult Patients With Pulmonary Arterial Hypertension (PAH) Ended

2023-510452-23-00 Pulmonary arterial hypertension 3 2024-10-29
Effects of Digoxin in Modern Heart Failure Treatment Ended

2024-513448-26-00 Heart Failure 6 2024-10-29